Corporate | 30 March 2011 07:45
Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Final
Results
30.03.2011 / 07:45
Berlin, March 30, 2011. The Berlin company Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700), a specialist for isotope
applications in medicine, science and industry, has once again been able to
increase its sales and the result from ongoing business operations in 2010.
The group sales proceeds thereby grew largely organically initially to EUR
111 million, an increase of about 10% compared to the already strong
previous year in terms of growth (2009: EUR 101 million). The result after
tax and minority interests rose by 26% from EUR 7.5 million to EUR 9.4
million, whereby in the previous year the special items increasing the
profit for comparison purposes were eliminated.
The result per share was EUR 1.81 and is lower than the adjusted value from
the previous year (EUR 1.97) because the number of shares rose more in the
fiscal year with 37% than the adjusted result with 26%.
In terms of business volume the segment that has seen the absolutely
strongest growth figures is again the segment of Isotope Products, in which
the sales figures rose from EUR 46.3 million in the previous year to EUR
50.8 million in 2010. Of this increase EUR 0.8 million can be attributed to
the baseline effect of a firm acquisition, the rest to an increased demand,
in particular for products for nuclear medicine imaging. In contrast the
largest relative growth was achieved with 16% increase to EUR 22.6 million
by the segment Radiopharmaceuticals. Here it was the sales of therapeutic
Yttrium-90 for cancer treatment as well as manufacturing machines for
clinics in particular that grew noticeably. In the segment Radiation
Therapy the sales with prostate carcinoma implants and tumor radiation
equipment declined slightly; however, through the sale of plant items to
Russia the segment was able to increase its sales by EUR 1.8 million to
EUR 32.1 million in spite of this. The new segment of environmental
services is still in the start-up phase and rose by 3% to EUR 5.6 million.
The board of directors and supervisory board will suggest an increase in
the dividends from EUR 0.45 to 0.60 per share at the shareholders' meeting
on 19th May 2011.
Sales of between EUR 110 and 120 million and a result after tax and
minority interests of at least EUR 10 million are expected for the fiscal
year 2011. By the end of 2014 the board of directors is expecting a
profitable increase in sales to around EUR 200 million per year.
With around 550 employees the Eckert & Ziegler Group belongs to the largest
providers of isotope components for radiotherapy and nuclear medicine
worldwide.
End of Corporate News
---------------------------------------------------------------------
30.03.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Deutschland
Phone: 49 30 941084-138
Fax: 49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, Düsseldorf, Hamburg, München
End of News DGAP News-Service
---------------------------------------------------------------------
117501 30.03.2011